A previous study showed that SGLT-2 inhibitors can mimic the previously mentioned states by promoting catabolism, restoring mTOR cycling, and reducing cognitive impairment linked to metabolic disorders (Stanciu et al. 2021). The gene discussed is MTOR; the disease is Other metabolic disease.